Correlation Engine 2.0
Clear Search sequence regions


  • amyloid (18)
  • amyloidosis (5)
  • Arg1 (2)
  • factors (1)
  • fibrils (3)
  • humans (1)
  • mass (2)
  • patients (2)
  • peptides (6)
  • proteins subunits (1)
  • SAA1 (2)
  • SAA2 (2)
  • Ser2 (1)
  • serum amyloid (5)
  • Sizes of these terms reflect their relevance to your search.

    AA amyloidosis is a disease caused by extracellular deposition of insoluble β-pleated sheet fibrils composed of amyloid A (AA) protein, an amino (N)-terminal fragment of serum amyloid A (SAA). The deposits disrupt tissue structure and compromise organ function. Although the disease is systemic, deposition in kidney glomeruli is the most common manifestation. The leading cause of AA amyloidosis is sustained or recurrent inflammation accompanied by elevated levels of SAA. Factors determining the conversion of SAA to AA amyloid fibrils have yet to be fully resolved. Herein, we present liquid chromatography tandem-mass spectrometry (LC-MS/MS) analysis of AA proteins purified from eight patients with AA amyloidosis. For the first time, post-translational modifications (PTM), including carbamylation, acetylation and oxidation, were identified on AA peptides; all eight samples showed some degree of PTM. The amyloid in 6 samples comprised peptides derived from SAA1 with few or none from SAA2, while the other two samples contained both SAA1- and SAA2-derived peptides. N-terminal AA peptides beginning with Arg1 as well as AA peptides starting with Ser2 were present in five of the eight samples, while all or nearly all of the N-terminal peptides in the other three samples lacked Arg1. These data demonstrate that multiple species of AA amyloid proteins can comprise the subunits in amyloid fibrils and raise the possibility that PTM may play a role in fibrillogenesis.

    Citation

    Barbara Kluve-Beckerman, Justin T Smith, Carlie Ivancic, Merrill D Benson. Post-translational modification of amyloid a protein in patients with AA amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2022 Mar;29(1):50-57

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34787027

    View Full Text